
Opsonil50 mg
Opsonin Pharma Ltd.
Chlorpromazine Hydrochloride is a first-generation (typical) phenothiazine antipsychotic.
Chlorpromazine Hydrochloride is a first-generation (typical) phenothiazine antipsychotic. Its evidence-based uses include:
Chlorpromazine Hydrochloride is not approved for treatment of dementia-related psychosis in elderly patients (see Precautions and Warnings for the boxed warning).
| Indication | Typical Dose |
|---|---|
| Psychotic disorders (outpatient) | 10 mg 3–4 times daily, or 25 mg 2–3 times daily; increase gradually as needed and tolerated |
| Psychotic disorders (hospitalized/severe) | 25 mg 3 times daily initially, increasing every 1–2 days up to 400 mg/day or more in resistant cases (some patients have required up to 800–2000 mg/day under close monitoring) |
| Nausea and vomiting | 10–25 mg orally every 4–6 hours as needed; 25–50 mg intramuscularly every 3–4 hours if oral route not feasible |
| Intractable hiccups | 25–50 mg 3–4 times daily |
| Preoperative apprehension | 25–50 mg 2–3 hours before surgery |
Approximately 0.55 mg/kg body weight orally every 4–6 hours as needed, or rectally/intramuscularly per specialist guidance. Maximum recommended daily dose is generally 40 mg for children under 5 years and 75 mg for children aged 5–12 years, unless otherwise directed by a physician. Chlorpromazine Hydrochloride is not recommended in children under 6 months of age except when potentially life-saving.
Start at approximately half the usual adult dose with slower dose titration, due to increased sensitivity to sedative and hypotensive effects.
May be taken with food or milk to reduce gastrointestinal irritation. Oral concentrate must be diluted before use. Intramuscular injection should be given deep into a large muscle mass; avoid subcutaneous injection due to tissue irritation. Dosage of Chlorpromazine Hydrochloride must always be individualized by the treating physician.
Common side effects of Chlorpromazine Hydrochloride include:
Less common but clinically important effects include tardive dyskinesia (risk increases with duration of therapy), neuroleptic malignant syndrome (rare but potentially life-threatening — see Precautions and Warnings), agranulocytosis and other blood dyscrasias (rare), cholestatic jaundice, QT interval prolongation and cardiac arrhythmias, and corneal/lenticular pigment deposits with long-term high-dose therapy.
Chlorpromazine Hydrochloride is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.